FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1443-1450 October 9, 2003 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Supplementary Material Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

A healthy, sexually active, 35-year-old woman presents for advice about the use of oral contraceptives. She does not smoke cigarettes and has no personal or family history of venous thromboembolism, myocardial infarction, or stroke. Her blood pressure is 120/80 mm Hg. Should an oral contraceptive be prescribed, and if so, how should a formulation be chosen?

The Clinical Problem

Most oral contraceptives now in widespread . . . [Full Text of this Article]

Strategies and Evidence

Benefits of Oral-Contraceptive Use

            Ovarian Cancer

            Endometrial Cancer

            Acne

            Menstrual Disorders, Loss of Blood, and Anemia

Risks Associated with Oral-Contraceptive Use

            Myocardial Infarction and Ischemic Stroke

            Venous Thromboembolism and Cerebral Venous Thrombosis

Evidence of No or Minimal Effect

Areas of Uncertainty

Particular Progestins and Vascular Disease

Screening for Thrombophilia

Hypertension and Other Cardiovascular Risk Factors

Migraine

Breast Cancer

Cervical Cancer

Other Neoplasia

Other Formulation-Specific Effects

Guidelines

Conclusions and Recommendations

Source Information

From the Research and Evaluation Department, Kaiser Permanente Southern California, Pasadena.

Address reprint requests to Dr. Petitti at Research and Evaluation, Kaiser Permanente Southern California, 100 S. Los Robles, 2nd Fl., Pasadena, CA 91188, or at diana.b.petitti@kp.org.

Related Letters:

Combined Estrogen–Progestin Oral Contraceptives
Martinelli I., Battaglioli T., Mannucci P. M., Sutherland S. E., Munarriz R. M., Goldstein I., Petitti D. B.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:307-308, Jan 15, 2004. Correspondence

This article has been cited by other articles:

• Kaunitz, A. M. (2008). Hormonal Contraception in Women of Older Reproductive Age. NEJM 358: 1262-1270 [Full Text]  
• Pruissen, D. M. O., Slooter, A. J. C., Rosendaal, F. R., van der Graaf, Y., Algra, A. (2008). Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 111: 1282-1286 [Abstract] [Full Text]  
• Hedderson, M. M., Ferrara, A., Williams, M. A., Holt, V. L., Weiss, N. S. (2007). Androgenicity of Progestins in Hormonal Contraceptives and the Risk of Gestational Diabetes Mellitus. Diabetes Care 30: 1062-1068 [Abstract] [Full Text]  
• (2006). New Hormonal Contraceptives Offer Patients More Choices. JWatch Women's Health 2006: 1-1 [Full Text]  
• James, A. H., Jamison, M. G., Biswas, M. S., Brancazio, L. R., Swamy, G. K., Myers, E. R. (2006). Acute Myocardial Infarction in Pregnancy: A United States Population-Based Study. Circulation 113: 1564-1571 [Abstract] [Full Text]  
• James, A. H., Ragni, M. V., Picozzi, V. J. (2006). Bleeding Disorders in Premenopausal Women: (Another) Public Health Crisis for Hematology?. ASH Education Book 2006: 474-485 [Abstract] [Full Text]  
• Rosenfield, R. L. (2005). Hirsutism. NEJM 353: 2578-2588 [Full Text]  
• Egred, M, Viswanathan, G, Davis, G K (2005). Myocardial infarction in young adults. Postgrad. Med. J. 81: 741-745 [Abstract] [Full Text]  
• The ESHRE Capri Workshop Group, (2005). Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 11: 513-525 [Abstract] [Full Text]  
• Baillargeon, J.-P., McClish, D. K., Essah, P. A., Nestler, J. E. (2005). Association between the Current Use of Low-Dose Oral Contraceptives and Cardiovascular Arterial Disease: A Meta-Analysis. J. Clin. Endocrinol. Metab. 90: 3863-3870 [Abstract] [Full Text]  
• Greer, J. B., Modugno, F., Allen, G. O., Ness, R. B. (2005). Androgenic Progestins in Oral Contraceptives and the Risk of Epithelial Ovarian Cancer. Obstet Gynecol 105: 731-740 [Abstract] [Full Text]  
• Yasuda, S., Suiko, M., Liu, M.-C. (2005). Oral Contraceptives as Substrates and Inhibitors for Human Cytosolic SULTs. J Biochem 137: 401-406 [Abstract] [Full Text]  
• Berchuck, A., Schildkraut, J. M., Wenham, R. M., Calingaert, B., Ali, S., Henriott, A., Halabi, S., Rodriguez, G. C., Gertig, D., Purdie, D. M., Kelemen, L., Spurdle, A. B., Marks, J., Chenevix-Trench, G. (2004). Progesterone Receptor Promoter +331A Polymorphism is Associated with a Reduced Risk of Endometrioid and Clear Cell Ovarian Cancers. Cancer Epidemiol. Biomarkers Prev. 13: 2141-2147 [Abstract] [Full Text]  
• Ibanez, L., de Zegher, F. (2004). Ethinylestradiol-Drospirenone, Flutamide-Metformin, or Both for Adolescents and Women with Hyperinsulinemic Hyperandrogenism: Opposite Effects on Adipocytokines and Body Adiposity. J. Clin. Endocrinol. Metab. 89: 1592-1597 [Abstract] [Full Text]  
• Martinelli, I., Battaglioli, T., Mannucci, P. M., Sutherland, S. E., Munarriz, R. M., Goldstein, I., Petitti, D. B. (2004). Combined Estrogen-Progestin Oral Contraceptives. NEJM 350: 307-308 [Full Text]